HUP0401429A2 - Lumirakoxibot tartalmazó gyógyszerkészítmény - Google Patents

Lumirakoxibot tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0401429A2
HUP0401429A2 HU0401429A HUP0401429A HUP0401429A2 HU P0401429 A2 HUP0401429 A2 HU P0401429A2 HU 0401429 A HU0401429 A HU 0401429A HU P0401429 A HUP0401429 A HU P0401429A HU P0401429 A2 HUP0401429 A2 HU P0401429A2
Authority
HU
Hungary
Prior art keywords
treatment
cyclooxygenase
mediated diseases
lumiracoxib
pharmaceutical composition
Prior art date
Application number
HU0401429A
Other languages
English (en)
Inventor
Anees Abdulquadar Karnachi
Simon David Bateman
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0401429A2 publication Critical patent/HUP0401429A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány készítményre vonatkozik ciklooxigenáz-2 által közvetítettbetegségek kezelésére, és az eljárásra a ciklooxigenáz-2 általközvetített betegségek kezelésére. A találmány szerinti készítménykörülbelül 65 tömeg% 5-metil-2-(2'klór-6'-fluor-anilino)-fenil-ecetsavhatóanyagot vagy sóját, és segédanyagokként polivinilpirrolidont,croscarmellose-nátriumot, magnézium-sztearátot és mikrokristályoscellulózt tartalmaz. A kezelést napi egy, azonnal felszabadulótablettával végzik, amely körülbelül 400 mg hatóanyagot tartalmaz. Abeadás orálisan történik. Ó
HU0401429A 2001-08-31 2002-08-30 Lumirakoxibot tartalmazó gyógyszerkészítmény HUP0401429A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31638901P 2001-08-31 2001-08-31
PCT/EP2002/009701 WO2003020261A1 (en) 2001-08-31 2002-08-30 Pharmaceutical composition comprising lumiracoxib

Publications (1)

Publication Number Publication Date
HUP0401429A2 true HUP0401429A2 (hu) 2004-11-29

Family

ID=23228840

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401429A HUP0401429A2 (hu) 2001-08-31 2002-08-30 Lumirakoxibot tartalmazó gyógyszerkészítmény

Country Status (30)

Country Link
US (2) US20030114527A1 (hu)
EP (1) EP1425005B1 (hu)
JP (1) JP4636796B2 (hu)
KR (1) KR100895551B1 (hu)
CN (1) CN100406008C (hu)
AR (1) AR036312A1 (hu)
AT (1) ATE324883T1 (hu)
AU (1) AU2002331094B2 (hu)
BR (1) BR0212155A (hu)
CA (1) CA2456604C (hu)
CO (1) CO5560554A2 (hu)
CY (1) CY1106137T1 (hu)
DE (1) DE60211183T2 (hu)
DK (1) DK1425005T3 (hu)
EC (1) ECSP044986A (hu)
ES (1) ES2263813T3 (hu)
HK (1) HK1087336A1 (hu)
HU (1) HUP0401429A2 (hu)
IL (1) IL160375A0 (hu)
MX (1) MXPA04001933A (hu)
MY (1) MY137516A (hu)
NO (1) NO20040860L (hu)
NZ (1) NZ531342A (hu)
PE (1) PE20030323A1 (hu)
PL (1) PL367464A1 (hu)
PT (1) PT1425005E (hu)
RU (1) RU2329801C2 (hu)
SI (1) SI1425005T1 (hu)
WO (1) WO2003020261A1 (hu)
ZA (1) ZA200400877B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
AU2003227039B2 (en) * 2002-03-07 2007-04-19 Novartis Ag Pharmaceutical compositions
US8148414B2 (en) 2008-08-19 2012-04-03 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
ES2903149T3 (es) 2012-05-14 2022-03-31 Shionogi & Co Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
ES2750323T3 (es) * 2014-01-10 2020-03-25 Johnson & Johnson Consumer Inc Método para la fabricación de un comprimido mediante radiofrecuencia y partículas recubiertas con pérdida
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246515T1 (de) * 1993-06-08 2003-08-15 Novartis Pharma Gmbh Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
TR199802345T2 (xx) * 1996-05-17 1999-03-22 Merck & Co., Inc. Siklooksijenaz-2-arac�l� hastal�klarda g�nde bir kez tatbikat i�in bile�imler.
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2

Also Published As

Publication number Publication date
EP1425005A1 (en) 2004-06-09
RU2329801C2 (ru) 2008-07-27
IL160375A0 (en) 2004-07-25
NO20040860L (no) 2004-04-22
AU2002331094B2 (en) 2006-08-31
CN100406008C (zh) 2008-07-30
ECSP044986A (es) 2004-04-28
WO2003020261A1 (en) 2003-03-13
CO5560554A2 (es) 2005-09-30
EP1425005B1 (en) 2006-05-03
ZA200400877B (en) 2004-11-01
PE20030323A1 (es) 2003-05-12
ES2263813T3 (es) 2006-12-16
PL367464A1 (en) 2005-02-21
JP4636796B2 (ja) 2011-02-23
NZ531342A (en) 2005-09-30
SI1425005T1 (sl) 2006-12-31
US20030114527A1 (en) 2003-06-19
ATE324883T1 (de) 2006-06-15
CY1106137T1 (el) 2011-06-08
JP2005520785A (ja) 2005-07-14
CA2456604C (en) 2011-02-08
CA2456604A1 (en) 2003-03-13
AR036312A1 (es) 2004-08-25
DE60211183T2 (de) 2007-02-01
BR0212155A (pt) 2004-07-13
MY137516A (en) 2009-02-27
HK1087336A1 (en) 2006-10-13
PT1425005E (pt) 2006-09-29
MXPA04001933A (es) 2004-06-15
RU2004109920A (ru) 2005-04-20
KR100895551B1 (ko) 2009-04-29
DK1425005T3 (da) 2006-09-04
CN1728993A (zh) 2006-02-01
DE60211183D1 (de) 2006-06-08
KR20040031019A (ko) 2004-04-09
US20070231382A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
HUP0401429A2 (hu) Lumirakoxibot tartalmazó gyógyszerkészítmény
US20200281886A1 (en) Methods and compositions for treating excessive sleepiness
CA2601289A1 (en) Once-a-day oxycodone formulations
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
HUP0203680A2 (hu) Szabályozott hatóanyag-leadású hidrokodon készítmények
HUP0402293A2 (hu) Fexofenadint tartalmazó szájban diszpergálódó tablettakészítmény, bevonatos granulátum és eljárás az előállítására
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
AU4903700A (en) Chronotherapeutic diltiazem formulations and the administration thereof
HUP0302068A2 (hu) COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
CA2416771A1 (en) 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
RU2003109606A (ru) Фармацевтические композиции
NO20054360L (no) Nye oxazolderivater, deres fremstilling og anvendelse som farmasotiske preparater
DE602004016963D1 (en) Therapeutisches system mit amoxicillin und clavulansäure
JP5467800B2 (ja) 唾液分泌促進剤及び唾液分泌促進用組成物
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial
HUP0300079A2 (en) Use of (r)-(-)-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its salts for preparation of pharmaceutical compositions

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees